Sorry, you need to enable JavaScript to visit this website.

Coronaviruses comprise a large family of viruses, some of which cause respiratory illnesses in humans, ranging from common colds to more severe conditions.1 The coronavirus involved in the outbreak that began in 2019 was named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).2 The disease it causes was named “coronavirus disease 2019” or “COVID-19.”2

From the beginning of the pandemic, we understood that fighting COVID-19 would require the power of science and unprecedented collaboration among scientists, companies, governments, and other stakeholders around the world.

Since 2020, we have been working on a multi-pronged approach to address COVID-19 and today we are focused on prevention through vaccinations, detection, and treatment for appropriate adult patients through medication. While there have been advancements in the fight against COVID, there is still more work to be done. At Pfizer, we remain unwavering in our commitment to combatting COVID-19.

COVID-19 Vaccine: Prevention through getting eligible people vaccinated is critical in helping the fight against COVID-19. That’s why, in 2020, we set out to make the impossible possible. In collaboration with BioNTech, we delivered a breakthrough COVID-19 vaccine to the world using messenger RNA (mRNA) technology, which is a molecule that contains the instructions or recipe that directs the cells to make a protein using its natural machinery.

Watch Exploring mRNA Technology on YouTube.

We worked with tremendous urgency, without compromising quality, coordinating closely with trial participants and investigators, regulatory bodies, other companies, and governments to bring this vaccine forward. Our success was made possible in part due to Pfizer’s longstanding history in vaccine research, development, and delivery, which dates back more than a century.

COVID-19 Treatment: In early 2020, recognizing the urgency of the COVID-19 pandemic around the world, Pfizer initiated a drug discovery program in an effort to develop a treatment for SARS-CoV-2 virus, complementing our vaccination efforts. We assembled a committed, multidisciplinary team to support the development of treatment intended for those with COVID-19 that might be high risk for progression to severe COVID-19.

Pfizer researchers identified an oral protease inhibitor to progress into clinical studies. On December 22, 2021, the U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) for the treatment of eligible patients diagnosed with COVID-19 at high risk of progressing to severe illness. On May 25, 2023, the FDA approved for the treatment of mild-to-moderate COVID-19 in adults who are at high risk for progression to severe COVID-19, including hospitalization or death.

Since 2020, we have continued to scale up our at-risk manufacturing efforts to expand vaccine and treatment access to different countries, based on local authorization or approval. Billions of Pfizer-BioNTech COVID-19 vaccines and tens of millions of oral COVID-19 treatment courses have been distributed to countries around the world.

We remain committed to working toward broad, equitable, and affordable access to Pfizer and BioNTech’s COVID-19 vaccine and Pfizer’s COVID-19 oral antiviral treatment for eligible patients around the world and are working with governments and other appropriate partners on a tailored approach.

In May 2023, three years after COVID-19 was designated as a pandemic, the World Health Organization (WHO) and the U.S. Department of Health and Human Services (HHS) declared the end of the Public Health Emergency (PHE) for COVID-19.3,4 While clinical and real-world data still show that existing COVID-19 vaccine options can help protect against the virus, we are continuing to follow the science by exploring new vaccine approaches that may be needed as the virus evolves. We also continue to run a COVID-19 clinical development program, consisting of completed and ongoing clinical trials, to evaluate our oral therapy for potential use in additional patient populations.

Our goal is to stay ahead of the virus by continuing to progress cutting-edge science that we believe may help serve patients in need. We are proactively advancing a multi-pronged strategy to evaluate additional treatment candidates as well as the potential for combination therapy.

In the meantime, we believe that one of the best safeguards against the spread of COVID-19 is getting all eligible people up to date with their vaccination schedule, and for those who do get COVID-19, educating and encouraging them to speak with their healthcare professional about available treatment options.

We remain committed  to working toward broad, equitable, and affordable access to Pfizer’s COVID-19 vaccine and oral COVID-19 treatment for eligible patients around the world. To that end, we continue to work with governments and other appropriate partners on a tailored approach. While developing groundbreaking treatments and vaccines for COVID-19 are crucial, we do not feel we are fulfilling our broader commitment to patients if we don’t work to make our vaccines and treatments accessible to every eligible person who needs them.


Albert Bourla announces an important agreement with the U.S. government that will make it easier for patients to access Pfizer’s oral antiviral treatment for COVID-19. This will help ensure that the United States will have a robust stockpile for future use and helps provide more clarity on the commercial market for COVID related products. This is the next logical step in Pfizer’s unrelenting effort to help ensure every eligible patient continues to have access to this potentially life-saving medicine.

This video includes forward-looking statements that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Please refer to Pfizer press release for more information.  We also encourage you to read our reports filed with the U.S. Securities and Exchange Commission (SEC), including the sections captioned “Risk Factors” and “Forward Looking Information and Factors that May Affect Future Results,” for a description of such substantial risks and uncertainties. These reports are available at and the SEC’s website. 

  • Like the flu, the virus that causes COVID-19 mutates often, which means it can escape the defenses your immune system built up against earlier strains. As of September 2023, about 85% of COVID-19 cases in the U.S. are caused by Omicron XBB strains5 and people who were vaccinated in past seasons may no longer be adequately protected because their body may not recognize the new strains. This season's vaccine is matched to the Omicron XBB.1.5 subvariant, while the previous bivalent vaccine was matched to the Omicron BA.4 and BA.5 sublineages.

  • The vaccine should be administered at least 2 months after the last dose of any COVID-19 vaccine.6 Talk  to your healthcare provider or pharmacist if you are unsure if you need an additional dose.

    If you recently had COVID-19, you still need to stay up to date with your vaccines, but you may consider delaying your next vaccine dose by 3 months from when your symptoms started or, if you had no symptoms, when you first received a positive test.

  • Talk to your healthcare provider about taking over-the-counter (OTC) medicine, such as ibuprofen, acetaminophen, aspirin (only for people ages 18 years or older), or antihistamines.7

  • While vaccines are one of the best ways individuals can help reduce the risk of infection, COVID-19 cases are still possible, and some people are at high risk for severe illness. Therefore, it is important that we have access to testing and treatment options for individuals that are diagnosed with COVID-19. This is why both vaccines and treatment options are necessary to help reduce the larger burden of COVID-19 disease in the world.

  • COVID-19 oral treatments may be right for you, even if you are vaccinated, if you are at high risk of progressing to severe illness. Talk to your doctor for individual medical advice.

  • Clinical and real-world data show that COVID-19 vaccines can help protect against COVID-19, particularly against the risk for severe disease and hospitalization. However, if you do get sick, have symptoms of COVID-19, and have a high risk factor for progression to severe illness, you should speak with your doctor about treatment options as soon as possible.

  • Side effects may vary depending on the individual and which vaccine is administered. Be sure to consult a healthcare provider to make decisions that are right for your medical history.

    Safety is a top concern for all of us and Pfizer takes reports of side effects that are potentially associated with our COVID-19 vaccines very seriously. While hundreds of millions of people have taken the vaccine safely, it is important to note that every medicine—and vaccine—has side effects.8 These side effects are rigorously monitored in clinical trials to ensure the benefits outweigh the risks.9

    More detailed information is available on the CDC’s Possible Side Effects After Getting a COVID-19 Vaccine page. Please visit our Coronavirus Resources page for more information about Pfizer’s work on COVID-19. 

Emergency Use Authorization

Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula) has not been approved or licensed by FDA, but has been authorized for emergency use by FDA, under an EUA to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals 6 months through 11 years of age. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b) (1) of the FD&C Act unless the declaration is terminated or authorization revoked sooner. Please see EUA Fact Sheets at

U.S. FDA Emergency Use Authorization Statement

The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the emergency use of PAXLOVID for the treatment of adults and pediatric patients (12 years of age and older weighing at least 40 kg) with mild-to-moderate coronavirus disease 2019 (COVID-19) and who are at high risk for progression to severe COVID-19, including hospitalization or death.

PAXLOVID is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of PAXLOVID under 564(b)(1) of the Food Drug and Cosmetic Act unless the authorization is terminated or revoked sooner.